BeOne Medicines (ONC) Free Cash Flow (2015 - 2026)

BeOne Medicines (ONC) has reported Free Cash Flow for 12 consecutive years, with $437.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Free Cash Flow rose 96.0% year-over-year to $437.8 million in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 443.29% increase from a year earlier, with the FY2025 full-year figure at $941.7 million, up 248.71% from the prior year.
• Free Cash Flow was $437.8 million for Q2 2026 at BeOne Medicines, up from $158.1 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $437.8 million in Q2 2026 and troughed at -$689.4 million in Q1 2023.
• A 5-year average of -$146.5 million and a median of -$220.8 million in 2023 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow sank 461.88% in 2022 and jumped 2292.98% in 2025, its largest moves.
• Over 5 years, Free Cash Flow stood at -$439.5 million in 2022, then gained by 13.87% to -$378.6 million in 2023, then jumped by 95.43% to -$17.3 million in 2024, then jumped by 2292.98% to $379.8 million in 2025, then rose by 15.26% to $437.8 million in 2026.
• The last three Free Cash Flow figures came in at $437.8 million (Q2 2026), $158.1 million (Q1 2026), and $379.8 million (Q4 2025), per Business Quant data.